Evidence map›Paper›PMID 40827409›Full record

Observational studyCancer medicine2025

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Yian Zhang, Yuhong Ren, Jingli Zhuang, Ling Yuan, Zhimei Wang, Xuejiao Zhang, Weiguang Wang, Zhixiang Cheng, Luya Cheng, Jing Li and 1 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06203652 (The Pathogenesis and Prognostic Factors of Lymphoma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06203652 recruitingnot on this map

The Pathogenesis and Prognostic Factors of Lymphoma

Typeobservational_patient_registrySponsorShanghai Zhongshan HospitalRan2023 to 2028Enrolled2,000ConditionsLymphoma, Hodgkin Lymphoma, Non-hodgkin LymphomaArmsReal-world regimen
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yian ZhangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-4033-211X
Yuhong RenDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingli ZhuangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ling YuanDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhimei WangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xuejiao ZhangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Weiguang WangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhixiang ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Luya ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jing LiDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-9639-6606

Funding

Natural Science Foundation of Shanghai Municipality 22ZR1411400
6 · The paper itself

Abstract

backgroundApproximately 30% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or are refractory to first-line treatment. This study aimed to determine the effectiveness and tolerability of the combination of Polatuzumab vedotin and Zanubrutinib plus Rituximab (Pola-ZR) or Obinutuzumab (Pola-ZG) in patients with relapsed/refractory (R/R) DLBCL.

methodsWe conducted a prospective observational study as part of our registered cohort study (NCT06203652). Patients were planned to receive six 21-day cycles of Pola-ZR/G, followed by Zanubrutinib monotherapy. The primary endpoint was to evaluate the best overall response rate (BOR), while secondary endpoints included the median progression-free survival (mPFS), safety, and complete response rate (CRR). We collected data from 73 R/R DLBCL patients who received traditional salvage therapies (TST). After propensity score matching, they were paired 1:1 with the Pola-ZR/G arm to compare the effectiveness and survival outcomes.

resultsTwenty-two patients were enrolled (median age 68 years) in the Pola-ZR/G group. After a median follow-up of 16.1 months, the investigators assessed BOR; it was 70% (77.77% for Pola-ZR and 63.6% for Pola-ZG cohort), and CRR was 45% in 20 evaluable R/R patients. The mPFS was 8.3 months and was higher compared to the TST cohort. The median overall survival (OS) of the Pola-ZR/G cohort had not been reached at the time of analysis. The most common grade 3 to 4 adverse events were infections of all types and hematological toxicity.

conclusionIn our study, patients derived clinical benefit after receiving Pola-ZR/G compared to TST; the regimens had a tolerable safety profile in patients with R/R DLBCL.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseNeoplasm Recurrence, LocalRituximabAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDrug Resistance, NeoplasmFemaleHumansImmunoconjugatesMaleMiddle AgedPiperidinesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmunoconjugatesobinutuzumabPiperidinespolatuzumab vedotinPyrazolesPyrimidinesRituximabzanubrutinibdiffuse large B‐cell lymphomaeffectivenessPolatuzumab vedotinrelapsed/refractorysafety

Identifiers

PMID40827409
PMCPMC12361929

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.